09:45 AM EDT, 06/17/2025 (MT Newswires) -- Citius Oncology ( CTOR ) said Tuesday that it has nearly completed preparations for the commercial launch of Lymphir to treat relapsed or refractory cutaneous T-cell lymphoma.

The company said it has completed commercial-scale manufacturing of Lymphir, with enough to meet projected demand for 12 to 18 months after the product launches.

The company said it expects to roll out Lymphir beginning in H2.

Price: 1.32, Change: -0.07, Percent Change: -5.04